Gates Vascular Institute

Slides:



Advertisements
Similar presentations
Single Center Experience with Drug Eluting Stents for Infrapopliteal Occlusive Disease in Patients with Critical Limb Ischemia: Mid-term follow up Robert.
Advertisements

Advanced Treatment Options for Stroke Patients Vickie Gordon PhD, ACNP-BC, CNRN.
Update on Anti-platelets Gabriel A. Vidal, MD Vascular Neurology Ochsner Medical Center October 14 th, 2009.
Viabahn Covered Stents for Cephalic Arch Stenosis Can Improve Patency and Longevity of Upper Arm AV Fistulas Toufic Safa, MD, FACS Vascular & Endovascular.
FERNE/EMRA The Management of ED TIA Patients: What is the optimal outpatient work-up, treatment and disposition?
One Year Outcomes in Real World Patients Treated with Transcatheter Aortic Valve Implantation The ADVANCE Study Axel Linke University of Leipzig Heart.
1 Michael Dake, MD Research/Research Grants, Clinical Trial Support –W. L. Gore –Cook Medical Consulting Fees/Honoraria –W. L. Gore –Abbott Vascular Equity.
Jonathan A. Edlow, MD, FACEP Transient Ischemic Attack Patient Update: The Optimal Management of Emergency Department Patients With Suspected Cerebral.
Endovascular Management of Intracranial and Extracranial Atherosclerosis Rishi Gupta, MD Associate Professor of Neurology, Neurosurgery, and Radiology.
CURRENT CONCEPTS IN THE MANAGEMENT OF INTRACRANIAL ATHEROSCLEROTIC DISEASE Robert D. Ecker, M.D. ~Neurosurgery 59:S3-210-S3-218, 2006 Feb. 06, 07 VJ.
Aims To evaluate the technical and clinical outcome of percutaneous transluminal infra-popliteal angioplasties (PTIA) +/- stenting in a subgroup of patients.
Overview of new acute stroke trials Shawna Cutting, MD, MS Rush University Medical Center June 9, 2015.
Template Title Speaker Name Subtitle. Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity.
* Based on post hoc analysis of individual outcome events (N=19,185). 1 Data on file, Sanofi Pharmaceuticals, Inc. 2 Gent M. Circulation. 1997; 96 (suppl):
Endovascular treatment on tandem lesions of cranial arteries Xiao-Long Zhang, MD, PhD Department of Radiology Huashan Hospital,Fudan University Shanghai.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Consensus of ICAD treatment after SAMMPRIS in China Zhujiang Hospital Zhujiang Hospital Nanfang Medical University Liu Yajie, MD Pros &Cons of PTAS in.
Title of Presentation Presenter Name, Designation Presenter 2 Name, Designation Presenter 3 Name, Designation.
CIT 2016 Template Title 40 pt Bold Arial David Liu, MD Subtitle 34 pt Arial Bold Italics.
Friedrich-Schiller-University, Jena, Germany
J Hermiller MD 1 Bifurcation Lesion Treatment Option: Insights From Clinical Literature James Hermiller, MD, FACC, FSCAI St Vincent Medical Group St Vincent.
Strategies to Improve Inadequate Guide Catheter Support John S Douglas Jr MD S Tanveer Rab MD Emory University School of Medicine Atlanta Georgia Sunday.
Carotid Disease – Stent vs Surgery vs Medical Therapy? Mehdi H. Shishehbor, DO, MPH, PhD Director, Endovascular Services Interventional Cardiology & Vascular.
Effect of Thrombus Aspiration in Patients With Myocardial Infarction Presenting Late After Symptom Onset Steffen Desch, MD Thomas Stiermaier, MD; Suzanne.
Purpose: The purpose of this study is to investigate the treatment results, and procedure-related complications of stent-angioplasty for symptomatic intracranial.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
Dr. Quan, Dr. Mirhashemi, Dr. Chiang
Simplifying Serial Lesion Assessment
David E. Kandzari, MD on behalf of the BIONICS investigators
Clinical Trials and Outcomes with DES in CTO Revascularization
Disclosure Statement of Financial Interest
Disclosures Speaker’s bureau: Research support: Consulting: Equity
VELOCITY A Prospective, Randomized Trial of Peritoneal Hypothermia in Patients with Acute STEMI Undergoing PCI Gregg W. Stone, MD Columbia University Medical.
Table 1: Table 2: Non Therapeutic Angiograms in Acute Ischemic Stroke Patients Being Considered for Endovascular Treatment Does not Adversely Affect Patient.
LAAO with Watchman Device Post-Procedure Best Practices
Updates From NOTION: The First All-Comer TAVR Trial
University at Buffalo Neurosurgery
Thrombectomy in Acute Stroke
Complex Ostial Disease of the Aortic Arch Vessels
Final Five-Year Follow-up of the SYNTAX Trial: Optimal Revascularization Strategy in Patients With Three-Vessel Disease and/or Left Main Disease Patrick.
Claret Cerebral Protection Device: Implications of the Sentinel Study
Renal Denervation Next Steps
Optimizing Valve Sizing: Role of CT vs. Echo
Manageing and Avoiding Complications in CAS
Surgical Mitral Valve Repair: What is the Gold Standard?
Clinical need for determination of vulnerable plaques
Kaleida Global Vascular Center UB Translational Research Center
Cardiovascular Research Technology Conference (CRT 17)
Cerebral aneurysm-single center experience
Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.
Disclosure Statement of Financial Interest
L. Nelson Hopkins, MD DISCLOSURES Consulting Fees
The Tryton Bifurcation Trial:
Selecting Patients Best Suited for CEA
FAVOR II Europe-Japan FAVOR II E-J
The Role of Interventional Treatment for The Failing Grafts
OCT-Guided PCI What needs to be done to establish criteria?
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Setareh Omran, MD Vascular Neurology Fellow
Tushar Trivedi1,2, Ravish Kothari
Modified Rankin score 0-2
The Role of Induced Hypertension and Hyperbaric Oxygen Therapy in Moyamoya Disease: A Case Report Smeer Salam, MD; Lisa Pabst, MD; Sushil Lakhani, MD;
Extended Window Thrombectomy
Title 40pt Trebuchet MS Bold
Disclosure Statement of Financial Interest
Disclosure Statement of Financial Interest
Transcarotid Artery Revascularization versus Transfemoral Carotid Artery Stenting for Treatment of Carotid Artery Stenosis Patric Liang, MD; Marc L.
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

Gates Vascular Institute Kaleida Global Vascular Center Jacobs Institute UB Translational Research Center Gates Vascular Institute

Intracranial Atherosclerotic Disease Techniques for Safe Intervention L. Nelson Hopkins, MD, FACS Professor of Neurosurgery Department of Neurosurgery – University at Buffalo President, Gates Vascular Institute, Buffalo, NY Vernard Fennell, MD, MSc Endovascular Fellow

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity Royalty Income Ownership/Founder Intellectual Property Rights Other Financial Benefit1 Toshiba, Medtronic, Microvention None Claret, Boston Scientific, Medina, Ostial, Apama, Ocular, Silk Road, TSP TSP

Intracranial Stenosis Common … Dangerous…Treatable with Risk Natural Hx (Sx stenosis) is Poor Med therepy 12-24% 1 Yr M&M Coumadin is dangerous (WASID) Primary Stenting high risk Restenosis is common (25-40% BMS) 7-10% of Ischemic CVA’s 70-90,000 CVA’s 15-20% Recurr Rate Warning TIA- 20%

Pts with 70-99% symptomatic stenosis highest risk of stroke WASID Trial Aspirin = Coumadin for AIS prevention, BUT… Coumadin caused more hemorrhage Pts with 70-99% symptomatic stenosis highest risk of stroke 18-22% at 1 year …an opportunity for endovascular treatment ??

Rapid stenting of symptomatic 70-99% intracranial stenosis Randomized 451 patients to Wingspan Stent or Aggressive medical therapy, 2008-2013 Rapid stenting of symptomatic 70-99% intracranial stenosis All patients dosed aspirin and plavix ++ Biweekly checks & counseling

SAMMPRIS Results: 30-day rate of the primary endpoint 14.7% PTAS vs. 5.8% AMM 1-year rate of the primary endpoint 20.0% PTAS vs. 12.2% AMM

SAMMPRIS: What Happened? Recently sx “Hot” plaques stented acutely A little goes a log way Wire perforation & Dissection Reperfusion hemorrhage “Snow plow” Perforator infarction “Cheesegrater” effect = infarction or perforation Vessel Rupture

SAMMPRIS Trial What Did We Learn Wingspan stent for recently symptomatic intracranial stenosis is dangerous Really aggressive medical therapy is somewhat effective (12% at one year) but not practical in general population SAMMPRIS stopped intervention for intracranial stenosis… A disaster for patients

Could the answer come from an old solution?

Case 45 year old man presents with left hand numbness TIA. Cardioembolic workup was negative, but angiography confirmed right MCA near-occlusive stenosis.

1.25 Balloon

6 months post-plasty: no symptoms

Submaximal Angioplasty: UBNS Experience 2007-2011 41 patients: 1 year stroke-free survival 93% 2 perioperative complications Vessel perforation: pt died POD 4 Reperfusion hemorrhage: MRS 3 -> 4 1 30 day – 1 year ischemic event

UB Angioplasty Experience Compares Favorably to SAMMPRIS Data

Stroke-Free Survival: UB Data

Complication 1: Reperfusion Hemorrhage Case 8: A 76 year old woman presented with a large MCA infarction, MRS score of 3 on presentation. Submaximal angioplasty of the right MCA was performed without incident. On postoperative day 1, she was found to have a neurological decline with diminished level of arousal. Noncontrast CT revealed a right frontal reperfusion hemorrhage. MRS at discharge Lesson Less dilitation is better

Complication 2: Vessel Perforation Case 10: A 67 year old woman underwent right MCA angioplasty. Intraoperatively, with microwire manipulation, extravasation was noted. Postoperative noncontrast CT revealed diffuse subarachnoid hemorrhage. She died of complications from the hemorrhage on postoperative day 4. Lesson Extreme care Soft wires

Complication 3: 30-day to 1 year Delayed stroke -A 50 year old man developed confusion four months after initial angioplasty. -Lost to FU…No 3 Month angio… -MRI was consistent with subacute ischemic event (arrows) ipsilateral to prior MCA angioplasty. -Revision angioplasty with placement of stent was performed. -No further sx Lesson Meticulous follow up

Sub-maximal angioplasty

Endovascular Treatment Symptomatic Intracranial Atherosclerotic Disease Our Approach Staged Angioplasty and Stent Submaximal Angioplasty (2/3 Reference vessel) Allow Healing 2-3 months Repeat imaging Delayed Stent (undersized) PRN

Sub-Maximal Angioplasty Safe and Effective 65 patient s w/ ICAD 75% w/ anterior circulation stenosis Stroke rate post sub max angioplasty 0% at 30d 5.5% at 1 year Mortality + hemorrhage 0%

Conclusions ICAD carries a high risk of stroke Stenting “hot” lesions is dangerous Sub-maximal angioplasty carefully performed is safe and effective Subsequent recurrent stenosis can be safely treated with slightly undersized stents

Thank you!